26159-34-2
26159-34-2
Chemical Structure
Naproxen sodium
- CAS No.: 26159-34-2
- Formula:C14H13NaO3
- Molecular Weight:252.24
IUPAC Name: sodium (S)-2-(6-methoxynaphthalen-2-yl)propanoate
InChIKey: CDBRNDSHEYLDJV-FVGYRXGTSA-M
SMILES: C[C@H](C(O[Na])=O)C1=CC2=CC=C(OC)C=C2C=C1
Biological Activity: Naproxen sodium is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Naproxen sodium | 99.74% | Naproxen sodium is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naproxen sodium (Standard) | ≥98% | Naproxen (sodium) (Standard) is the analytical standard of Naproxen (sodium). This product is intended for research and analytical applications. Naproxen sodium is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AKR1C2/3-IN-2 | AKR1C2/3-IN-2 is a potential AKR1C3 inhibitor with selective AKR1C3 activity. AKR1C2/3-IN-2 is able to block AKR1C3-mediated testosterone (T) production and PSA induction, affecting the endocrine activity of prostate cancer cells. AKR1C2/3-IN-2 shows selectivity over other AKR1C enzymes, indicating its potential application in inhibiting drug-resistant prostate cancer. AKR1C2/3-IN-2 has no inhibitory activity against COX isomerases, further emphasizing its specificity as a prostate cancer inhibitory compound. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naproxen methyl ester | Naproxen methyl ester is a prodrug of Naproxen (HY-15030) and an ester derivative. Naproxen methyl ester is promising for research of arthritis and other inflammatory conditions1. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Naproxen | 99.79% | (±)-Naproxen ((Rac)-Naproxen) is the racemate of Naproxen (HY-15030), consisting of R- and S-enantiomers. (±)-Naproxen binds to AKR1C3, which preferentially recognizes the R-enantiomer from the racemic mixture. It is used for AKR1C3 stereoselective ligand recognition and studies on NSAID binding mechanisms. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(±)-Naproxen-13C,d3 | 99.06% | (±)-Naproxen-13C,d3 ((Rac)-Naproxen-13C,d3) is the 13C, deuterated-labeled (±)-Naproxen (HY-15029). (±)-Naproxen ((Rac)-Naproxen) is the racemate of Naproxen (HY-15030), consisting of R- and S-enantiomers. (±)-Naproxen binds to AKR1C3, which preferentially recognizes the R-enantiomer from the racemic mixture. It is used for AKR1C3 stereoselective ligand recognition and studies on NSAID binding mechanisms. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naproxen (Standard) | 99.91% | Naproxen (Standard) is the analytical standard of Naproxen. This product is intended for research and analytical applications. Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naproxen-d3 | Naproxen-d3 ((S)-Naproxen-d3) is the deuterium labeled Naproxen (HY-15030). Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
l-Naproxen | 99.85% | l-Naproxen ((R)-Naproxen) is an enantiomer of (S)-Naproxen. l-Naproxen can inhibit Cdc42 and Rac1 (EC50=96 μM and 212 μM, respectively), and show anti-tumor activity. l-Naproxen is a nonsteroidal antiinflammatory agent (NSAID). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naproxen etemesil | 99.89% | Naproxen etemesil is a lipophilic, non-acidic, inactive proagent of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
α-Demethylnaproxen | 99.76% | α-Demethylnaproxen is the major metabolite of Nabumetone (HY-B0559), Nabumetone is an orally active COX-2 inhibitor with anti-inflammatory activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Naproxen ethyl ester | Naproxen ethyl ester ((S)-Naproxen ethyl ester) is a nonsteroidal anti-inflammatory drug with activity in relieving pain, fever, swelling and stiffness. Naproxen ethyl ester exerts its effects by inhibiting non-selective cyclooxygenase (COX). The R-(-)-isomer of Naproxen ethyl ester shows stronger immunogenicity, and the Michaelis-Menten parameter of its catalytic reaction is K(M)=6.67 mM, and the catalytic efficiency is 5.8 x 10^4 times higher than that of the non-catalytic reaction. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
